Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Immutep Trial Discontinuation, Class Action
Business class action

Immutep Trial Discontinuation, Class Action

Analysis based on 40 articles · First reported Apr 01, 2026 · Last updated May 05, 2026

Sentiment
-70
Attention
4
Articles
40
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The discontinuation of Immutep's clinical trial led to a significant drop in its stock price, negatively impacting investors. This has prompted Rosen Law Firm to initiate a class action investigation, potentially leading to financial recovery for affected shareholders.

Biotechnology Legal Services
Event Summary

Immutep announced the discontinuation of its TACTI-004 Phase III study for non-small cell lung cancer on March 13, 2026, following an interim futility analysis. This news caused Immutep's American Depositary Receipt (ADR) price to fall by 82.6% to $0.48 per ADR. In response, Rosen Law Firm is investigating potential securities claims against Immutep, alleging the company may have issued misleading business information. The firm is preparing a class action lawsuit to recover investor losses, with attorneys Philip Kim and Lawrence Rosen listed as contacts for affected shareholders.

Key Actions
90 Rosen Law Firm investigates claims Immutep
87 Immutep issued press release
Entities Involved
stock
Immutep
Immutep's stock price fell significantly after the discontinuation of its TACTI-004 Phase III study, leading to a class action investigation by Rosen Law Firm.
Importance 100 Sentiment -90
priv
Rosen Law Firm
Rosen Law Firm is investigating potential securities claims against Immutep and is preparing a class action lawsuit on behalf of investors who suffered losses.
Importance 90 Sentiment 50
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is listed as a contact for investors interested in joining the class action against Immutep.
Importance 60 Sentiment 20
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is mentioned for his firm's track record in securities class actions and is a contact for the Immutep investigation.
Importance 60 Sentiment 20
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.